News

NantKwest’s Vax-DC/MM cell therapy has induced a partial or complete response in 42 percent of relapsed or refractory multiple myeloma (MM) and lymphoma patients in a…

The U.S. Food and Drug Administration (FDA) has approved Imbruvica (ibrutinib) for the treatment of chronic graft-versus-host-disease (cGVHD), a common complication of stem cell or bone…

Sutro Biopharma‘s STRO-001 eliminates or significantly slows the growth of non-Hodgkin lymphoma and multiple myeloma tumors, studies in mice indicate. Sutro expects the results to support…

Revlimid (lenalidomide) therapy maintenance has been shown to delay disease progression and extend survival in newly diagnosed multiple myeloma (NDMM) patients who receive a transplant…

Stem cell transplants derived from patients’ own bone marrow are a safe and effective treatment for those with multiple myeloma who fail to respond to first-line…

The Cancer Support Community (CSC), a nonprofit advocacy organization, recently released a research report about the emotional, social, and financial burdens on cancer patients. The…

Kyprolis (carfilzomib), when given with dexamethasone, lets relapsed myeloma patients live an average 7.6 months longer than those treated with  Velcade (bortezomib) with dexamethasone — information that …

Adding the proteasome inhibitor Kyprolis (carfilzomib) to the standard regimen of Revlimid (lenalidomide) and dexamethasone reduced the risk of…

Kadmon reports that the first patient group treated in a Phase 2 trial of its drug KD025 for chronic graft-versus-host disease after going through…

The Multiple Myeloma Research Foundation will be pumping $15 million into a cancer immunotherapy initiative over the next three years. The effort will start with the…